Literature DB >> 16078828

Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone.

Prakash G Jagtap1, Erkan Baloglu, Garry J Southan, Jon G Mabley, Hongshan Li, Jing Zhou, John van Duzer, Andrew L Salzman, Csaba Szabó.   

Abstract

Novel indeno[1,2-c]isoquinolinone derivatives were synthesized and evaluated as inhibitors of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1). These potent nonmutagenic PARP-1 inhibitors possess an additional five-membered ring between the B and C rings of 6(5H)-phenanthridinone. The most potent PARP-1 inhibitors were obtained from the substitution of the D ring at the C-9 position, in particular sulfonamide and N-acyl analogues (6 and 11). The 9-sulfonamide analogues 11a and 12a exhibited IC(50) values of 1 and 10 nM, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078828     DOI: 10.1021/jm0502891

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 2.  Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP).

Authors:  Badar Ul Islam; Safia Habib; Parvez Ahmad; Shaziya Allarakha; Asif Ali
Journal:  Indian J Clin Biochem       Date:  2015-01-20

3.  Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.

Authors:  Soo-Kyoung Choi; Maria Galán; Modar Kassan; Megan Partyka; Mohamed Trebak; Khalid Matrougui
Journal:  Hypertension       Date:  2012-03-26       Impact factor: 10.190

Review 4.  Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies.

Authors:  Dimitris Tousoulis; Nikolaos Papageorgiou; Alexandros Briasoulis; Emmanouel Androulakis; Marietta Charakida; Eleftherios Tsiamis; Christodoulos Stefanadis
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

5.  Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction.

Authors:  Tamás Radovits; Leila Seres; Domokos Gero; Irina Berger; Csaba Szabó; Matthias Karck; Gábor Szabó
Journal:  Exp Gerontol       Date:  2007-02-20       Impact factor: 4.032

Review 6.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 7.  Regulated necrosis: disease relevance and therapeutic opportunities.

Authors:  Marcus Conrad; José Pedro Friedmann Angeli; Peter Vandenabeele; Brent R Stockwell
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

Review 8.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

Review 9.  The Role of Poly(ADP-Ribose) Polymerase-1 in Cutaneous Wound Healing.

Authors:  Jaideep Banerjee; Niraj Lodhi; Bao-Ngoc Nguyen
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-11-06       Impact factor: 4.730

Review 10.  Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.

Authors:  A Peralta-Leal; M I Rodríguez; F J Oliver
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.